Transgenic expression of the coxsackie/adenovirus receptor enables adenoviral-mediated gene delivery in naive T cells

被引:71
作者
Wan, YY
Leon, RP
Marks, R
Cham, CM
Schaack, J
Gajewski, TF
DeGregori, J
机构
[1] Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet & Pediat, Denver, CO 80262 USA
[2] Univ Colorado, Hlth Sci Ctr, Dept Microbiol, Denver, CO 80262 USA
[3] Univ Colorado, Hlth Sci Ctr, Program Mol Biol, Denver, CO 80262 USA
[4] Univ Chicago, Med Ctr, Dept Pathol, Chicago, IL 60637 USA
[5] Univ Chicago, Med Ctr, Dept Med, Chicago, IL 60637 USA
[6] Univ Chicago, Med Ctr, Comm Immunol, Chicago, IL 60637 USA
[7] Univ Chicago, Med Ctr, Comm Canc Biol, Chicago, IL 60637 USA
关键词
D O I
10.1073/pnas.250356297
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The inability to easily and efficiently introduce genes into primary T cells has hampered the investigation of the pathways controlling T cell fate. To enable adenoviral-mediated gene transfer into normal naive T cells, transgenic (Tg) mice expressing the coxsackie/adenovirus receptor (CAR) in their T cell compartment were constructed. Whereas naive T cells are resistant to adenoviral infection, Tg expression of CAR on T cells greatly facilitates adenoviral-mediated gene expression ex vivo in vivo, and in differentiated T helper cells. Thus we have developed a technology for efficient gene delivery to naive T cells. By using adenoviral vectors encoding specific inhibitors, we show that CI cyclin-dependent kinase. NF-kappaB, and caspase activities are required for the proliferation of primary T cells. In addition, by expressing Bcl-x(L) protein at a level that closely approximates mitogen-induced levels, we demonstrate that Bcl-x(L) expression is sufficient to account for mitogen-mediated survival of primary T cells. Thus, adenoviral-mediated gene delivery to CAR Tg T cells should be useful for the analysis of many genes controlling T cell fate.
引用
收藏
页码:13784 / 13789
页数:6
相关论文
共 32 条
[1]   Early activation of caspases during T lymphocyte stimulation results in selective substrate cleavage in nonapoptotic cells [J].
Alam, A ;
Cohen, LY ;
Aouad, S ;
Sékaly, RP .
JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 190 (12) :1879-1890
[2]   P53 is essential for developmental neuron death as regulated by the TrkA and p75 neurotrophin receptors [J].
Aloyz, RS ;
Bamji, SX ;
Pozniak, CD ;
Toma, JG ;
Atwal, J ;
Kaplan, DR ;
Miller, FD .
JOURNAL OF CELL BIOLOGY, 1998, 143 (06) :1691-1703
[3]   The NF-kappa B and I kappa B proteins: New discoveries and insights [J].
Baldwin, AS .
ANNUAL REVIEW OF IMMUNOLOGY, 1996, 14 :649-683
[4]   Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5 [J].
Bergelson, JM ;
Cunningham, JA ;
Droguett, G ;
KurtJones, EA ;
Krithivas, A ;
Hong, JS ;
Horwitz, MS ;
Crowell, RL ;
Finberg, RW .
SCIENCE, 1997, 275 (5304) :1320-1323
[5]   Structural analysis of the mechanism of adenovirus binding to its human cellular receptor, CAR [J].
Bewley, MC ;
Springer, K ;
Zhang, YB ;
Freimuth, P ;
Flanagan, JM .
SCIENCE, 1999, 286 (5444) :1579-1583
[6]   CD28 COSTIMULATION CAN PROMOTE T-CELL SURVIVAL BY ENHANCING THE EXPRESSION OF BCL-X(L) [J].
BOISE, LH ;
MINN, AJ ;
NOEL, PJ ;
JUNE, CH ;
ACCAVITTI, MA ;
LINDSTEN, T ;
THOMPSON, CB .
IMMUNITY, 1995, 3 (01) :87-98
[7]   Perturbation of the T lymphocyte lineage in transgenic mice expressing a constitutive repressor of nuclear factor (NF)-kappa B [J].
Boothby, MR ;
Mora, AL ;
Scherer, DC ;
Brockman, JA ;
Ballard, DW .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 185 (11) :1897-1907
[8]   BCL-X(L) AND BCL-2 REPRESS A COMMON PATHWAY OF CELL-DEATH [J].
CHAO, DT ;
LINETTE, GP ;
BOISE, LH ;
WHITE, LS ;
THOMPSON, CB ;
KORSMEYER, SJ .
JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 182 (03) :821-828
[9]   Expression of Bcl-XL restores cell survival, but not proliferation and effector differentiation, in CD28-deficient T lymphocytes [J].
Dahl, AM ;
Klein, C ;
Andres, PG ;
London, CA ;
Lodge, MP ;
Mulligan, RC ;
Abbas, AK .
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 191 (12) :2031-2037
[10]  
Ferreira V, 1999, J IMMUNOL, V162, P6442